Prescient starts US recruitment in Phase 2a trial of PTX-100 for patients with rare blood cancer

• Prescient initiates first US site for Phase 2a trial of PTX 100 in patients with rare blood cancer r/r CTCL.
• The newly activated site is renowned VCU Massey Comprehensive Cancer Centre in Virginia
• Site adds to three existing Australian sites, where four people have been enrolled

Special Report: Prescient Therapeutics has reached a key milestone in its clinical development program, initiating its first US site for the Phase 2a trial of PTX-100 in patients with rare blood cancer relapsed/refractory Cutaneous T-Cell Lymphoma (r/r CTCL).

The newly activated site is at VCU Massey Comprehensive Cancer Center in Richmond, Virginia, and adds to the three Australian Phase 2a trial sites for Prescient Therapeutics (ASX:PTX), where four patients have already been enrolled.

PTX-100 is a first-in-class compound with the ability to block an important cancer growth enzyme geranylgeranyl transferase-1 (GGT-1). It is believed to be the only GGT-1 inhibitor in the world in clinical development.

Chief medical officer Dr Marissa Lim said Prescient was pleased to have completed the first US site initiation visit at the VCU Massey Comprehensive Cancer.

“This is part of the Virginia Commonwealth University (VCU) which is ranked as one of the top cancer research centers in the US,” she said.

“This site initiation marks the start of the US recruitment into the Phase 2a trial, allowing US patients to access PTX-100 through this trial.”

Watch: Prescient Therapeutics First US trial site launches for PTX-100

“Closer to turning long-held dream into meaningful impacts”

Progression of the Phase 2a trial marks a professional high point for scientific founder of Prescient Professor Said Sebti.

“As a cancer researcher, there is no greater fulfillment than seeing a drug you co-invented in the laboratory begin to touch patients’ lives,” he said.

“The launch of this global Phase 2 clinical trial of PTX-100 in r/r CTCL, is one of the most exhilarating and humbling moments of my career, and a powerful reminder of what science can achieve when driven by purpose and passion.

“I’m profoundly proud that VCU Massey Comprehensive Cancer Center, my academic home, is the first US site to open for patient accrual, bringing us one step closer to turning a long-held dream into meaningful impact for patients.”

Prescient Therapeutics CEO James McDonnell said completion of the first site initiation visit in the US at VCU represented another step forward in the progress of its Phase 2a trial.

“The first US site adds to the three Australian sites and four patients currently enrolled,” he said.

“We look forward to additional trial sites being initiated in the coming weeks, to add to the ongoing accrual of patients into the Phase 2a trial.”

This article was developed in collaboration with Prescient Therapeutics, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.